Dermatology

Update on Bimatoprost Ophthalmic Solution 0.03% Lumigan®, Ustekinumab (CNTO-1275) Centocor, p53 tumor suppressor therapy ADVEXIN®, Shingles Vaccine Zostavax®, Calcipotriene 0.005% + betamethasone dipropionate 0.064% Xamiol® Gel, and Etanercept Enbrel®.

Update on Anti-psoriatic Agent Adalimumab (Humira®), Antihistamine (Claritin®), HIV drug Etravirine (Intelence™) and news about new antioxidant, coffeeberry (REVALÉSKIN™, Stiefel Laboratories)

Update on: Tissue Engineered Collagen Matrix Oasis Wound Dressing Bexarotene Targretin Gel 1% Eflornithine Hydrochloride Vaniqa Cream 15% Biologically Active Dressing Composite Cultured Skin (CCS) Famciclovir Famvir Moxifloxacin Avelox/Avalox Finasteride 1mg Tablets Propecia

Update on drugs, approval dates, and comments. Drospirenone /ethinyl estradiol /levomefolate calcium + levomefolate calcium tablets (Beyaz™), Imiquimod 5% cream are covered.

Update on: Famciclovir Famvir® Acyclovir sodium Zovirax® Calcipotriol Dovonex® Thalidomide 50 mg Thalomid® Finasteride 1mg tablets Propecia® Aids vaccine Aidsvax® phase III, Indinavir Crixivan® Calcipotriene 0.005% Dovonex®ointment

Update on Ustekinumab Stelara®, Photopheresis System THERAKOS™ CELLEX™, Calcitriol Vectical™ Ointment, Autologous Collagen Cellular Processing System Isolagen Therapy™.

Update on Certolizumab pegol Cimzia® UCB S.A., Golimumab Centocor, Ceftobiprole medocaril ZEFTERA® Basilea Pharmaceuticals, and Tipranavir Aptivus® Boehringer-Ingelheim.

Update on Minocycline HCl SOLODYN™ Extended Release Tablets, Linezolid ZYVOX® 600mg, Tigecycline Tygacil®, and CF-1743.

Update on drugs, approval dates, and comments. Calcipotriene/Calcipotriol0.005% foam (Sorilux™), Ceftaroline fosamil (Teflaro™) are covered as well as an update on Health Canada on the use of tacrolimus (Protopic®) for atopic dermatitis.

Update on CD56-binding monoclonal antibody (huN901) + maytansinoid cytotoxic agent (DM1) IMGN901, Small molecule oxychlorine compound (Microcyn® Skin and Wound HydroGel), Antifungal agent (K101/Kaprolac®).

An overview and update of skin treatments introduced in 2012: Quick overview of drug name, indications and regulatory status. Adapalene 0.1% + benzoyl peroxide 2.5% gel (Epiduo®), Adapalene 0.3% gel (Differin®), Tazarotene 0.1% foam (Fabior™), CIP-Isotretinoin capsule Epuris™ (in Canada) Absorica™ (in US) and more drugs are covered.

Updates on Ustekinumab Stelara® Centocor Ortho Biotech, Romidepsin ISTODAX® Gloucester Pharmaceuticals and news from US FDA.

Updates on: Tretinoin Gel Microsphere Retin-A® Micro 0.04% Cyclosporine capsules 25mg, 100mg Gabapentin Neurontin® Docosanol 10% Cream Salicylic Acid 15% Trans-Ver-Sal® Wart Removal Patch

Update on Nanocrystalline Silver Cream NPI32101, Daptomycin for Injection CUBICIN®, Oral Alitretinoin BAL4079, Smallpox Vaccine ACAM2000, and news about new US FDA regulations.

Update on: Amphotericin B Lipid Complex Injection Abelcet®Butenafine HCl Cream 1% Mentax® Itraconazole Sporanox® Acitretin Soriatane® Penciclovir cream 1% Denavir® Valacyclovir Valtrex® Laser device Sharplan Silktouch laser® Permethrin lotion Nix® Ivermectin Mectizan® (6 mg tablet)

Update on drugs, approval dates, and comments. Velaglucerase alfa (VPRIV®) and Health Canada labelling changes for isopropyl myristate 50% rinse (Resultz®, Nycomed) to include the treatment of lice in children =2 years of age are covered.

Update on drugs, approval dates, and comments. Spinosad 0.9% cream rinse (Natroba™), Light emitting diode (LED) skin rejuvenation system (Tanda™ Professional Rejuvenate), Voclosporin Voclera™ (ISA247) are covered.

Update on Doxycycline Oracea® CollaGenex, Hydrogel Dressing MimyX™ Cream Stiefel Laboratories, and Aluma™ Skin Renewal System with FACES™ Lumenis.

Update on Polymethylmethacrylate/ Bovine Collagen ArteFill® Artes Medical, Polyphenon® E Ointment 15% MediGene AG/ Bradley Pharmaceuticals, and drug news on melanoma and new vaccines.

Update on: Pyrethrins/Piperonyl butoxide Rid aerosol foam mousse Fluocinolone acetonide 0.01% Derma-Smoothe/FS Quinupristin/ Dalfopristin Synercid IV Rid Lice Egg Loosener Gel Tacrolimus Protopic Ointment Docosanol

Update on drugs, approval dates, and comments. Ivermectin 0.5% lotion (Sklice™), Ipilimumab (Yervoy™), Vemurafenib (Zelboraf®), are covered, as well as the Cellulite removal laser device Cellulaze™ Cellulite Laser Workstation.

This index covers all articles published in Skin Therapy Letter Dermatology Edition articles in 2021. Articles are indexed by drug names, trade names and disease terms. Bold entries refer to major references.

Update on: Moxifloxacin HCl Avelox Recombinant Human Iduronidase (IDUA) Neurotoxins Botox Graftskin Apligraf

Update on Diclofenac Sodium 3% Gel Solaraze®, Retapamulin Ointment 1% Altabax™, Calcium Hydroxylapatite Microspheres in Water-based Gel Radiesse®, Rose Bengal Disodium 10% PV-10, and Taxane Potentiator STA-4783.

Drug Treatments Introduced in 1998

Update on Alitretinoin (Toctino®), Denileukin Diftitox (Ontak™), Bimatoprost Ophthalmic 0.03% Solution (LATISSE®), Maraviroc (SELZENTRY®), Clindamycin Phosphate 1.2% + Benzoyl Peroxide 2.5% (Acanya® Gel), Etanercept (Enbrel®).

Update on: Tazarotene 0.1% Tazorac® Botulinum Toxin BOTOX® Tacrolimus Ointment Protopic® Amlexanox 5% paste Aptheal® Tenofovir Disoproxil Fumarate Viread™ HIV Drug Resistance Test Trugene™ HIV-1 Genotyping Test

Update on Loratadine Dry Syrup 1% Claritin® Schering-Plough, Valacyclovir Hydrochloride TEVA Pharmaceutical Industries, and news about Anti-dandruff, anti-acne and anti-melanoma agents.

The update covers Difelikefalin for IV use - Korsuva™ (Vifor Pharma, Cara Therapeutics), Topical MEK inhibitor - NFX-179 (NFlextion Therapeutics), Maralixibat oral solution - Livmarli™ (Mirum Pharmaceuticals), Ruxolitinib cream 1.5% - Opzelura™ (Incyte), Ruxolitinib tablets - Jakafi® (Incyte), and Avacopan capsules - Tavneos™ (ChemoCentryx).

Drug update covering: Adalimumab-adbm for SC use - Cyltezo®, Tralokinumab for SC use - Adtralza® (in Canada), Tralokinumab-ldrm for SC use - Adbry™ (in US), Melanoma vaccine for IV use - BNT111, Adalimumab-aqvh for SC use - Yusimry™, and more...

Update on Golimumab (Simponi™) Centocor/Schering-Plough, Darunavir (PREZISTA™) Tibotec/Janssen-Ortho, Telavancin (Arbelic™) Theravance/Astellas, and news from US FDA.

A novel topical corticosteroid, halobetasol propionate (HP) 0.01% lotion (Bryhali™), has recently been introduced for the treatment of plaque psoriasis and corticosteroid-responsive dermatoses in adults.

Update on Capsaicin 8% Patch Qutenza™, Alitretinoin Capsule Toctino® as well as news about a recent study by Kenter et al.* explored the efficacy of a human papillomavirus (HPV) vaccine.

This update covers Nivolumab + Relatlimab-rmbw for IV use - Opdualag™ (Bristol-Myers Squibb), Sirolimus topical gel 0.2% - Hyftor™ (Nobelpharma America), Oral epinephrine - AQST-109 (Aquestive Therapeutics), and Bimekizumab for SC use - Bimzelx® (UCB Canada Inc.).

This update covers Adalimumab biosimilar - Yuflyma™ (Celltrion Healthcare), Adalimumab biosimilar - Simlandi™ (Alvotech/JAMP Pharma), Abrocitinib tablet - Cibinqo® (Pfizer), Upadacitinib tablet - Rinvoq® (AbbVie), Risankizumab-rzaa SC injection - Skyrizi® (AbbVie), and HA-based dermal filler - Juvéderm® Volbella® XC (AbbVie/ Allergan Aesthetics).